Lüftner, DI; Bartsch, R; Breitenstein, U; Jackisch, C; Mueller, V; Schmidt, M; Balic, M; Rinnerthaler, G; Zaman, K; Schwitter, M; Wrobel, D; Guth, D; Zaiss, M; Terhaag, J; Perlova-Griff, L; Wuerstlein, R; Schinköthe, T; Vannier, C; Harbeck, N.
Extended adjuvant neratinib in HER2+/HR+ early breast cancer in clinical routine: Final results from the multinational, prospective, observational study ELEANOR
ANN ONCOL. 2025; 36:
Doi: 10.1016/j.annonc.2025.08.728
Web of Science
FullText
FullText_MUG